CurrentCignaPolicy N/A

Phenylketonuria - Sephience Prior Authorization Policy

Prior authorization policy for coverage and medical necessity of Sephience (sepiapterin oral powder) for treatment of phenylketonuria (PKU) in Cigna-administered benefit plans.

Policy Summary

PayerCigna

PolicyPhenylketonuria - Sephience Prior Authorization Policy

Policy CodePolicy N/A

Change TypeNo material change

Effective DateN/A

Next Review DateJul 30, 2025

Key ActionObtain prior authorization; initial approvals are for 12 weeks and continuation approvals for 1 year when criteria are met.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

Age ≥ 1 moFDA indication lower age limit

12 wksInitial approval duration

1 yrContinuation approval

≥20%Response threshold

60 mg/kg/dayMax daily dose

Coverage Criteria for Sephience (sepiapterin)

Policy Summary

PayerCigna

PolicyPhenylketonuria - Sephience Prior Authorization Policy

Policy CodePolicy N/A

Change TypeNo material change

Effective DateN/A

Next Review DateJul 30, 2025

Key ActionObtain prior authorization; initial approvals are for 12 weeks and continuation approvals for 1 year when criteria are met.

SourceLink

On This Page

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

FDA-Approved Indication

Covered when ONE of the following is met

A) Initial Therapy
- A.i: The medication is prescribed in conjunction with a phenylalanine-restricted diet
- A.ii: The medication is prescribed by or in consultation with a metabolic disease specialist (or specialist who focuses on the treatment of metabolic diseases)
B) Currently Receiving Sephience
- B.i
  - B.i.a: Prescriber documents a clinical response (e.g., cognitive and/or behavioral improvements)
  - B.i.b: Patient has achieved ≥20% reduction in blood phenylalanine concentration from pre-treatment baseline≥20% reduction
  - B.i.c: Prescriber documents increased dietary phenylalanine tolerance
- B.ii: Patient is not receiving concomitant Palynziq (pegvaliase-pqpz) at a stable maintenance dose
  Concomitant use with Palynziq is permitted during Palynziq dose titration

Prior Authorization and Prescriber Requirements: Prior authorization is required; initial approvals are for 12 weeks and continuation approvals for 1 year. Initial therapy must be prescribed by or in consultation with a specialist due to required monitoring and specialized skills

From policy statement

Concurrent use of Sephience with sapropterin (Kuvan, Javygtor, generic) is not covered. Sapropterin is a synthetic form of tetrahydrobiopterin (BH4) and there are no available data on the safety or effectiveness of combining sapropterin with Sephience; therefore combination therapy is specifically excluded.

Sephience is considered not medically necessary for any uses not listed in this policy. This includes, but is not limited to, concurrent administration with sapropterin (Kuvan, Javygtor, generic), for which no clinical data on combination use exist; requests for such uses will be denied as not medically necessary.

Dosing, Biochemical Response, and Coding Notes

Biochemical response thresholds — responder thresholds and policy continuation threshold

Widely accepted responder threshold≥30% reduction in blood phenylalanine (Phe)

Policy continuation threshold≥20% reduction in blood Phe (acceptable for continuation approvals)

Assessment methodPercent reduction from pre-treatment baseline blood Phe concentration

Maximum daily dose — dosing limit

Maximum recommended daily dose60 mg/kg/day (maximum daily dose for all patients)

Starting dosages by age (examples)<6 months: 7.5 mg/kg/day; 6 months–<1 year: 15 mg/kg/day; 1–<2 years: 30 mg/kg/day; ≥2 years: 60 mg/kg/day

Titration noteFor patients <2 years, check blood Phe within 2 weeks and titrate to a maximum of 60 mg/kg/day if needed

Prior Authorization, Documentation, and Denial Risk

Prior Authorization

Prior Authorization Required

Prior authorization is required for both initial and continuation therapy. Initial approvals are for 12 weeks; continuation (patients currently receiving Sephience) approvals are for 1 year when renewal criteria are met. Prescriptions must be written by or in consultation with a metabolic disease specialist (or a specialist who focuses on treatment of metabolic diseases).

Initial therapy approval duration: 12 weeks
Continuation (current user) approval duration: 1 year

Denial Risk

Prohibited Concurrent Therapy — Denial Risk

Concurrent use of Sephience with sapropterin (Kuvan, Javygtor, generic) is considered not medically necessary and will be denied. There are no data regarding combination use of sapropterin and Sephience; do not authorize overlap. Note: Concomitant use with Palynziq (pegvaliase) is permitted only during Palynziq dose titration and not at stable maintenance dose.

Affected agents: sapropterin (Kuvan, Javygtor, generic)
Exception: Palynziq permitted during titration, not at stable maintenance dose

Documentation Required

Required Clinical Documentation

Required clinical documentation must be provided at initial authorization. The prescriber must be a metabolic disease specialist (or specialist who focuses on treatment of metabolic diseases) or the request must include documentation of consultation with such a specialist. For initial therapy, documentation must confirm use in conjunction with a phenylalanine‑restricted diet.

Prescriber specialty: metabolic disease specialist or consultation documentation
Initial therapy documentation: confirmation of phenylalanine‑restricted diet

Denial Risk

Not Medically Necessary Uses

Sephience is not medically necessary for any uses outside the FDA‑approved indication for phenylketonuria, including concurrent use with sapropterin. Requests for off‑label uses or combinations without supportive data will be denied.

Not medically necessary: any use other than FDA‑approved PKU indication
Specifically not covered: concurrent use with sapropterin (Kuvan, Javygtor, generic)

Clinical Background and Drug Overview

Phenylketonuria (PKU), caused by phenylalanine hydroxylase (PAH) deficiency, leads to elevated blood phenylalanine that can cause neurologic harm if untreated. Sephience (sepiapterin oral powder) is a BH4 precursor that increases cofactor availability to activate PAH and is indicated for sepiapterin-responsive hyperphenylalaninemia/PKU in patients aged ≥1 month. Therapy should be used with a phenylalanine-restricted diet; biochemical response is measured as a reduction in blood phenylalanine (a ≥30% decrease is widely accepted as responsive, though smaller reductions may be clinically meaningful in some cases).

Definitions and Key Terms

Sephience — product definition and mechanism (sepiapterin oral powder)

Generic / product descriptionSephience (sepiapterin oral powder)

Mechanism of actionSepiapterin is a precursor of tetrahydrobiopterin (BH4) that activates phenylalanine hydroxylase (PAH)

Indication contextIndicated for treatment of sepiapterin‑responsive hyperphenylalaninemia/phenylketonuria in patients ≥1 month of age; used with a Phe‑restricted diet

Biochemical response — definition and commonly accepted thresholds

Definition of biochemical responseReduction in blood phenylalanine (Phe) concentration compared with pre‑treatment baseline

Commonly accepted responder threshold≥30% reduction in blood Phe is widely accepted as indicative of biochemical response

Lower threshold considered clinically meaningfulA ≥20% reduction may be sufficient in some individual circumstances and is accepted by policy for continuation